These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17017952)

  • 21. Risk of infection associated with anti-TNF-α therapy.
    Fernández-Ruiz M; Aguado JM
    Expert Rev Anti Infect Ther; 2018 Dec; 16(12):939-956. PubMed ID: 30388900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation.
    Vielhauer V; Mayadas TN
    Semin Nephrol; 2007 May; 27(3):286-308. PubMed ID: 17533007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Campas-Moya C
    Drugs Today (Barc); 2010 Jan; 46(1):13-22. PubMed ID: 20200692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice.
    Winsauer C; Kruglov AA; Chashchina AA; Drutskaya MS; Nedospasov SA
    Cytokine Growth Factor Rev; 2014 Apr; 25(2):115-23. PubMed ID: 24405806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases.
    Willrich MA; Murray DL; Snyder MR
    Transl Res; 2015 Feb; 165(2):270-82. PubMed ID: 25305470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination.
    Gelinck LB; van der Bijl AE; Beyer WE; Visser LG; Huizinga TW; van Hogezand RA; Rimmelzwaan GF; Kroon FP
    Ann Rheum Dis; 2008 May; 67(5):713-6. PubMed ID: 17965123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary glands.
    Sisto M; D'Amore M; Caprio S; Mitolo V; Scagliusi P; Lisi S
    Ann N Y Acad Sci; 2009 Aug; 1171():407-14. PubMed ID: 19723083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-cytokine vaccination: a new biotherapy of autoimmunity?
    Semerano L; Assier E; Boissier MC
    Autoimmun Rev; 2012 Sep; 11(11):785-6. PubMed ID: 22349621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative for anti-TNF antibodies for arthritis treatment.
    Paquet J; Henrionnet C; Pinzano A; Vincourt JB; Gillet P; Netter P; Chary-Valckenaere I; Loeuille D; Pourel J; Grossin L
    Mol Ther; 2011 Oct; 19(10):1887-95. PubMed ID: 21811249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.
    Van Wijk F; Staecker H; Keithley E; Lefebvre PP
    Audiol Neurootol; 2006; 11(6):357-65. PubMed ID: 16988499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis.
    Kodama S; Davis M; Faustman DL
    Cell Mol Life Sci; 2005 Aug; 62(16):1850-62. PubMed ID: 15968469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Monoclonal antibodies for treating autoimmune diseases].
    Takeno M; Sakane T
    Nihon Rinsho; 1997 Jun; 55(6):1543-8. PubMed ID: 9200946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.
    Tyagi AM; Mansoori MN; Srivastava K; Khan MP; Kureel J; Dixit M; Shukla P; Trivedi R; Chattopadhyay N; Singh D
    J Bone Miner Res; 2014 Sep; 29(9):1981-92. PubMed ID: 24677326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications.
    Yang S; Wang J; Brand DD; Zheng SG
    Front Immunol; 2018; 9():784. PubMed ID: 29725328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.
    Bendtzen K
    Immunotherapy; 2012 Nov; 4(11):1167-79. PubMed ID: 23194366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases.
    Blandizzi C; Gionchetti P; Armuzzi A; Caporali R; Chimenti S; Cimaz R; Cimino L; Lapadula G; Lionetti P; Marchesoni A; Marcellusi A; Mennini FS; Salvarani C; Girolomoni G
    Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):1-10. PubMed ID: 24774503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can we design a better anti-cytokine therapy?
    Drutskaya MS; Efimov GA; Kruglov AA; Nedospasov SA
    J Leukoc Biol; 2017 Sep; 102(3):783-790. PubMed ID: 28546502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biological therapy of arthritis and systemic autoimmune diseases].
    Tamási L; Szekanecz Z
    Orv Hetil; 2007 Apr; 148 Suppl 1():63-70. PubMed ID: 17430797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.